Company Overview - Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [1][2] - The company aims to design and deliver novel, best-in-class monoclonal antibodies with enhanced selectivity and potency [1] Recent Developments - Dianthus Therapeutics announced its participation in several upcoming investor conferences, indicating active engagement with the investment community [1][2] - CEO Marino Garcia will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, and will also host one-on-one meetings with investors [2] - CFO Ryan Savitz will conduct one-on-one investor meetings at the Jefferies Biotech on the Bay Summit on March 12, 2025 [2]
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences